Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating

UniQure (NASDAQ:QURE) is one of the top gene therapy stocks to buy according to hedge funds. Wolfe Research initiated coverage of UniQure (NASDAQ:QURE) with a Peer Perform rating on February 23, without assigning a price target. The firm stated that it launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas”, adding that it requires additional clarity on UniQure’s (NASDAQ:QURE) lead program AMT-130 before recommending the shares. Is ...